FDA OK's Medicines' coronary angioplasty drug Kengreal
This article was originally published in Scrip
Executive Summary
Apparently already anticipating an approval from the FDA, Wall Street paid little attention on 22 June when the agency actually gave its nod to The Medicines Company (MDCO) to market its intravenous antiplatelet agent Kengreal (cangrelor) – the news of which only pushed shares of the firm up as high as 2.8%, or 82 cents.